ViraTherapeutics GmbH is a biotech company based in Innsbruck, Tyrol, Austria. The company was formed as a spin-off of the Medical University of Innsbruck in April 2013.
ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed.
ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients in 2018 at the earliest.
ViraTherapeutics is funded by JITU-Seedfinancing of the BMWFW executed by aws.